**Electronic medical record**

The Electronic medical record and genomics (eMERGE) network review1

**NHGRI, March 2007, Phase I [eMERGE-I]**

Five sites:

“In September 2007, grants were awarded to five sites (hereaf- ter referred to as eMERGE-I)—Group Health Cooperative/University of Washington, Marshfield Clinic, Mayo Clinic, Northwestern University, and **Vanderbilt University**, which also served as the network’s **coordinating center**.”  
eMERGE-II (9 sites):

CHOP [Children’s hospital of Philadelphia], GHC & U Wash, Mount Sinai, CCHMC & BCH [Cincinnati Children’s Hospital Medical Center with Boston Children’s Hospital], Marshfield & Essentia, Northwestern, Geiginger, Mayo, Vanderbilt

Three major aims:

1 EMR for robust electronic phenotyping;

2 conduct GWAS using the phenotypes derived in the above-mentioned first aim; PheGWAS2

3 explore the ethical, legal, and social implications associated with EMR-based GWAS and wide-scale data sharing.

The workgroups included:  
an informatics group [published a phenotyping algorithm, PheKb: Phenotype KnowledgeBase, 20http://www.PheKb.org]. Developed by the first site and deployed to the second, and then across the network.   
a genomics group [imputation, strand issue, relatedness, ],   
and a consent and community consultation group [model language for EMR-linked ].

**Lesson learned from Phase I**

1 Phenotyping across the network rather than local sites.

2 Most eMERGE Participants have consented to contributing their data to health research of any kind. Through network-wide projects, eMERGE-I was compelled to develop best practices for sharing genomic data and EMR-derived phenotypes while protecting the privacy of participants.

3 Returing of results (RoR) 3. Turner syndrome, Klinefelter syndrome, FVL, hereditary hemochromatosis. There is no clear agreement how the finding should be returned. In some case, the clinically actionable results identified in EMR was already known. “In some case, health records shed light on ambiguous findings, increasing the likelihood that some findings represented acquired rather than congenital genetic changes.”

**Phase II [eMERGE-II]**

Phenotyping workgroup

Genomics workgroup

RoR workgroup

Consent, education, regulation, and consultation workgroup: evaluating the impact of returning hemochromatosis results

EMR integration workgroup: PGx [pharmcogenomic] pilot project

Collaboration with external groups

**Lessons**

1 Portability of electronic phenotypes within and outside eMERGE

“There is currently no formal phenotyping language for the purpose of building EMR phenotyping algorithms nor is their a common approach to their implementation.

2 Approaches to EMR integration of genomic information

3 Integration of pediatric sites

4 Longitudinal cost-effective genomic medicine discovery and implementation

5 Generalized framework for the return of genomic results

6 The eMERGE network in the context of a translational framework.   
T0: early phases focusing of biologic discoveries (eMERGE-I focused large on T0)  
T1: development of candidate health applications (eMERGE-II)

T2: assessing outcomes of intervertions

T3: move genomic findings into health practice.

T4: public health surveillance

**Geisinger**4 **[The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research]**

**1996 started to collect EMR**

**2007 GHS launched a project now known as MyCode Community Health Initiative to create a system-wide biorepository of blood serum and DNA samples for broad research used, including genomic analysis.**

**In their demo, the loss-of-function *APOC3* was tested. *APOC3* had strong effect in lipd values**5

**GERA [Genetic Epidemiology Research on Adult Health and Aging cohort]**6

About a cohort of > 100,000 subjects who are participants in the Kaiser Permanente Medical Care Plan, Northern California Region. 20% African Africa, Asian, and Latino or mixed, 80% non-Hispanic white.

Affymetrix Axiom Genotyping chip designed by GERA7,8.

Saliva-based genotyping experiments, Oragene OG-250 disc format saliva kit.

Population genetics study analysis for GERA found about 3400 Chinese samples9.

GERA also measure Telomere Length10. It was pretty petty because mDNA provided a much accurate measure for aging compared with Telomere length11.

**Reference**

1. Gottesman, O. *et al.* The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. *Genet. Med.* **15**, 761–71 (2013).

2. Denny, J. C. *et al.* PheWAS: Demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics* **26**, 1205–1210 (2010).

3. Fullerton, S. M. *et al.* Return of individual research results from genome-wide association studies: Experience of the Electronic Medical Records and Genomics (eMERGE) Network. *Genet. Med.* **14**, 424–431 (2012).

4. Carey, D. J. *et al.* The Geisinger MyCode community health initiative: An electronic health record-linked biobank for precision medicine research. *Genet. Med.* **18**, 906–913 (2016).

5. The TG and HDL Working Group of the Exome Sequencing Project. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. *N. Engl. J. Med.* **371**, 22–31 (2014).

6. Kvale, M. N. *et al.* Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. *Genetics* **200**, 1051–1060 (2015).

7. Hoffmann, T. J. *et al.* Next generation genome-wide association tool: Design and coverage of a high-throughput European-optimized SNP array. *Genomics* **98**, 79–89 (2011).

8. Hoffmann, T. J. *et al.* Design and coverage of high throughput genotyping arrays optimized for individuals of East Asian, African American, and Latino race/ethnicity using imputation and a novel hybrid SNP selection algorithm. *Genomics* **98**, 422–430 (2011).

9. Banda, Y. *et al.* Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. *Genetics* **200**, 1285–1295 (2015).

10. Lapham, K. *et al.* Automated Assay of Telomere Length Measurement and Informatics for 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort. *Genetics* **200**, 1061–1072 (2015).

11. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, R115 (2013).